---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000210"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-07-13T23:59:59+00:00"
generated_at: "2026-06-30T05:44:51.863471+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma discloses full IP portfolio status with patent grants, allowances, and revival efforts

## Summary
- Granted US patents: BORIS gene silencing (8,263,571), NR2F6 anti-tumor methods (11,053,503), NR2F6 screening (10,088,485), NR2F6 modulation (9,091,696).
- Notice of allowance received for antigen-specific mRNA cancer vaccine (app. 15/162,370).
- Two patent assets in revival: siRNA cancer therapy (8,389,708) and universal donor cord blood killer cells (15/494,358).
- Active applications include NR2F6 inhibition combined with cannabidiol for cancer, angiogenesis, arthritis; small molecule NR2F6 modulators.
- Zander Therapeutics licensed patent for canine dendritic cell immunotherapy (10,030,227).

## SEC filing metadata
- accession: 0001607062-21-000210
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000210/0001607062-21-000210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000210/rgbp071321form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000210
- JSON: https://secwatch.observer/filing/0001607062-21-000210.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.